Sarepta Therapeutics (SRPT) Misses Q4 EPS by 7c, Revenue Misses

Sarepta Therapeutics (NASDAQ: SRPT) reported Q4 EPS of ($1.84), $0.07 worse than the analyst estimate of ($1.77). Revenue for the quarter came in at $122.6 million versus the consensus estimate of $146.3 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Benchmark Reiterates Buy Rating on H World Group Ltd. (HTHT) Following Q2 Print
• Cummins wins battery storage contract for U.S. data center project